Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $39.7 million.

  • Krystal Biotech's Cash from Operations fell 3261.8% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.2 million, marking a year-over-year increase of 17815.93%. This contributed to the annual value of $123.4 million for FY2024, which is 23898.02% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Cash from Operations is $39.7 million, which was down 3261.8% from $52.7 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Cash from Operations peaked at $58.9 million during Q3 2024, and registered a low of -$43.1 million during Q2 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$9.7 million (2021), whereas its average is $498210.5.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 32510.61% in 2022, then soared by 136509.12% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Cash from Operations stood at -$20.9 million in 2021, then dropped by 6.84% to -$22.3 million in 2022, then surged by 67.61% to -$7.2 million in 2023, then soared by 830.68% to $52.8 million in 2024, then decreased by 24.95% to $39.7 million in 2025.
  • Its Cash from Operations stands at $39.7 million for Q3 2025, versus $52.7 million for Q2 2025 and $31.0 million for Q1 2025.